This article is more than 5 years old. Information may no longer be current.

Cerapedics files premarket approval for peptide-enhanced bone graft

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Cerapedics announced it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration for i-FACTOR Peptide Enhanced Bone Graft.

Data from a clinical trial demonstrating that i-FACTOR bone graft can be used as an alternative to autograft harvesting in anterior cervical discectomy and fusion (ACDF) procedures supported the application. The clinical data were the last step in the premarket approval application, which was submitted by the company in modules, according to a press release from Cerapedics.

“The PMA filing is an important milestone in our effort to advance our proprietary synthetic small peptide (P-15) technology platform, which has the potential to provide significant benefits to patients and surgeons in the U.S. who currently rely on autograft and other less-studied bone graft products on the market today,” Glen Kashuba, CEO at Cerapedics, said in the press release.

Cerapedics presented preliminary outcomes data from an FDA Investigational Device Exemption clinical trial for the i-FACTOR bone graft in March.

With the PMA filing, final data from this trial have been submitted, according to the release.

Reference: www.cerapedics.com